R Squared Ltd Increases Stake in Sanofi $SNY

R Squared Ltd lifted its stake in shares of Sanofi (NASDAQ:SNY) by 189.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,030 shares of the company’s stock after buying an additional 17,050 shares during the quarter. Sanofi makes up approximately 0.7% of R Squared Ltd’s portfolio, making the stock its 19th biggest position. R Squared Ltd’s holdings in Sanofi were worth $1,254,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after acquiring an additional 1,869 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Sanofi by 107.2% in the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after purchasing an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after purchasing an additional 752 shares during the last quarter. Sivia Capital Partners LLC lifted its position in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after purchasing an additional 347 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Sanofi by 36.1% during the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock worth $159,000 after purchasing an additional 875 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 1.5%

Shares of NASDAQ SNY traded up $0.62 during mid-day trading on Tuesday, reaching $43.23. The company had a trading volume of 1,172,429 shares, compared to its average volume of 3,655,331. The firm has a 50 day simple moving average of $43.59 and a two-hundred day simple moving average of $45.79. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The stock has a market cap of $104.81 billion, a P/E ratio of 12.08, a PEG ratio of 1.07 and a beta of 0.34.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. The ex-dividend date of this dividend was Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. Sanofi’s dividend payout ratio is 49.16%.

Analyst Ratings Changes

A number of analysts have weighed in on the company. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Monday, April 20th. Morgan Stanley set a $52.00 price objective on Sanofi in a research report on Friday, May 1st. Citigroup reiterated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $51.00.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.